Mechanism of 6-hydroxydopamine neurotoxicity

  • Yelena Glinka
  • M. Gassen
  • M. B. H. Youdim
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 50)


The catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA) has recently been found to be formed endogenously in patients suffering from Parkinson’s disease. In this article, we highlight the latest findings on the biochemical mechanism of 6-OHDA toxicity. 6-OHDA has two ways of action: it easly forms free radicals and it is a potent inhibitor of the mitochondrial respiratory chain complexes I and IV. The inhibition of respiratory enzymes by 6-OHDA is reversible and insensitive towards radical scavengers and iron chelators with the exception of desferrioxamine. We conclude that free radicals ate not involved in the interaction between 6-OHDA and the respiratory chain and that the two mechanisms are biochemically independent, although they may act synergistically in vivo.


Dopaminergic Neuron Mitochondrial Respiration Iron Chelator Dopamine Neuron Mitochondrial Respiratory Chain Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Altar CA, Boyland CB, Fritsche M, Jones BE, Jackson C, Wiegand SJ, Lindsay RM, Hyman C (1993) Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. J Neurochem 63: 1021–1032CrossRefGoogle Scholar
  2. Andrew R, Watson DG, Best SA, Midgey H, Wenlong H, Petty RKH (1993) The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls. Neurochem Res 18: 1175–1177PubMedCrossRefGoogle Scholar
  3. Beal MF, Hyman BT, Koroshetz W (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 16: 125–131PubMedCrossRefGoogle Scholar
  4. Ben-Shachar D, Youdim MBH (1990) Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson’s disease may depend on iron-melanin interaction. J Neural Transm [Suppt] 29: 251–258Google Scholar
  5. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical “parkinsonism” in rats. J Neurochem 57: 2133–2135PubMedCrossRefGoogle Scholar
  6. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferoxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441–1444PubMedCrossRefGoogle Scholar
  7. Ben-Shachar D, Zuk R, Glinka Y (1994) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 64: 718–723CrossRefGoogle Scholar
  8. Cerruti C, Drian MJ, Kamenka JM, Privat A (1993) Protection by BTCP of cultured dopaminergic neurons exposed to neurotoxins. Brain Res 617: 138–142PubMedCrossRefGoogle Scholar
  9. Chadi G, Cao Y, Pettersson RF, Fuxe K (1994) Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons. Neuroscience 61: 891–910PubMedCrossRefGoogle Scholar
  10. Cohen G, Werner P (1994) Free radicals, oxidative stress, and neurodegeneration. In: Calne DB (ed) Neurodegenerative diseases. Saunders, Philadelphia, pp 139–162Google Scholar
  11. Decker DE, Althaus JS, Buxser SE, Von Voigtlander PF, Ruppel PL (1993) Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res Commun Chem Pathol Pharmacol 79: 195–208PubMedGoogle Scholar
  12. Dexter DT, Jenner P, Schapira AHV, Mardsen CD (1992) Alterations in level of iron, ferritin ans other trace metals in neurodegenerative disease affecting basal ganglia. Ann Neurol 32: 94–100CrossRefGoogle Scholar
  13. Erecinska M, Dagani F (1990) Relationship between the neuronal sodium/potassium pump and energy metabolism. Effects of K+, Na+, and adensine triphosphate in isolated brain synaptosomes. J Gen Physiol 95: 591–616PubMedCrossRefGoogle Scholar
  14. Filloux F, Townsend JJ (1993) Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119: 79–88PubMedCrossRefGoogle Scholar
  15. Gee P, San RH, Davison AJ, Stich HF (1992) Clastogenic and mutagenic actions of active species generated in the 6-hydroxydopamine/oxygen reaction: effects of scavengers of active oxygen, iron, and metal chelating agents. Free Radic Res Commun 16: 1–10PubMedCrossRefGoogle Scholar
  16. Glinka Y, Youdim MBH (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol Environ Toxicol Pharmacol 292: 329–332CrossRefGoogle Scholar
  17. Glinka Y, Gassen M, Youdim MBH (1996a) Iron and neurotransmitter function in brain. In: Connors JR (ed) Metals and oxidative damage in neurological disorders. Plenum Publishing Corp, New YorkGoogle Scholar
  18. Glinka Y, Tipton KF, Youdim MBH (1996b) Nature of inhibition of mitochondrial respiratory complex 1 by 6-hydroxydopamine. J Neurochem (in press)Google Scholar
  19. Gordon BG, DeBoer JM, Wooldridge LD, Sharp JG (1991) Effect of 6-hydroxydopamine on murine hepatopoetic stem cells: enhanced cytotoxicity on megakaryocyte colony forming units. Life Sci 49: 121–127PubMedCrossRefGoogle Scholar
  20. Inoue A, Ueda H, Nakata Y, Mizu Y (1994) Supersensitivity of quinpirole-evoked GTPase activation without changes in gene expression of D2 and Gi protein in the striatum of hemi-dopaminergic lesioned rats. Neurosci Lett 175: 107–110PubMedCrossRefGoogle Scholar
  21. Karoum F, Chrapusta SJ, Egan MF, Wyatt RJ (1993) Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study. J Neurochem 61: 1369–1375PubMedCrossRefGoogle Scholar
  22. Kebabian JW (1994) Neurotransmitter receptors in neurodegeneration. In: Calne DB (ed) Neurodegenerative diseases. Saunders, Philadelphia, pp 119–128Google Scholar
  23. Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF (1996) The role of the transition metals in the pathogenesis of Parkinson’s disease. J Neurol Sci 4766Google Scholar
  24. Kita T, Wagner GC, Philbert MA, King LA, Lowndes HE (1995) Effects of pargyline and pyrogallol on the methamphetamine-induced dopamine depletion. Mol Chem Neu-ropathol 24: 31–41CrossRefGoogle Scholar
  25. Kotlyar AB, Sled VD, Vinogradov AD (1992) Effect of Ca2+ ions on the slow active/inactive transition of the mitochondrial NADH-ubiquinone reductase. Biochim Biophys Acta 1098: 144–150PubMedCrossRefGoogle Scholar
  26. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163: 1450–1455PubMedCrossRefGoogle Scholar
  27. Mizuno Y, Shin-Ichiro I, Hattori N, Yoshino H (1993) Mitochondria in Parkinson’s disease. In: Calne DB, Horowski R, Mizuno Y, Poewe WH, Riederer P, Youdim MBH (eds) Advances in research on neurodegeneration. Birkhäuser, Boston, pp 55–66Google Scholar
  28. Monterio HP, Winterbourne CC (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 38: 4144–4182Google Scholar
  29. Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P (1992) Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferoxamine. Free Radic Biol Med 13: 499–508PubMedCrossRefGoogle Scholar
  30. Naveilhan P, Neveu I, Jehan F, Baudet C, Wion D, Brachet P (1994) Reactive oxygen species influence nerve growth factor synthesis in primary rat astrocytes. J Neurochem 62: 2178–2186PubMedCrossRefGoogle Scholar
  31. Offen D, Ziv I, Gorodin S, Barzilai A, Malik Z, Melamed E (1995) Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta 1268: 171–177PubMedCrossRefGoogle Scholar
  32. Orrenius S, Nicotera P (1994) The calcium ion and cell death. J Neural Transm [Suppl] 43: 1–11Google Scholar
  33. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bulletin 29: 699–701CrossRefGoogle Scholar
  34. Sampath D, Jackson GR, Werrbach-Perez K, Perez-Polo JR (1994) Effects of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. J Neurochem 62: 2476–2479PubMedCrossRefGoogle Scholar
  35. Schwartz JP, Nishiyama N (1994) Neurotrophic factor gene expression in astrocytes during development and following injury. Brain Res Bull 35: 403–407PubMedCrossRefGoogle Scholar
  36. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C (1992) Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of glutathione system. J Neurochem 59: 99–106PubMedCrossRefGoogle Scholar
  37. Stadtman ER (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Ann Rev Biochem 62: 797–821PubMedCrossRefGoogle Scholar
  38. Ueda H, Sato K, Okumura F, Inoue A, Nakata Y, Yue JL, Mizu Y (1995) Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson’s disease model rats. Biomed Pharmacother 49: 169–177PubMedCrossRefGoogle Scholar
  39. Vroegop SM, Decker DE, Buxser SE (1995) Localization of damage induced by reactive oxygen species in cultured cells. Free Radic Biol Med 18: 141–151PubMedCrossRefGoogle Scholar
  40. Yokoyama C, Okamura H, Ibata Y (1993) Resistance of hypothalamic dopaminergic neurons to neonatal 6-hydroxydopamine toxicity. Brain Res Bulletin 30: 551–559CrossRefGoogle Scholar
  41. Youdim MBH, Riederer P (1993) The role of iron in senescence of dopaminergic neuronsin Parkinson’s disease. J Neural Transm [Suppl] 40: 57–67Google Scholar

Copyright information

© Springer-Verlag Wien 1997

Authors and Affiliations

  • Yelena Glinka
    • 1
  • M. Gassen
    • 1
  • M. B. H. Youdim
    • 1
  1. 1.Department of PharmacologyBruce Rappaport Faculty of MedicineHaifaIsrael

Personalised recommendations